Abstract 706MO
Background
Data related to the impact of human papillomavirus (HPV) infection status and the outcome of perioperative treatments in patients with lymph node-involved penile squamous-cell carcinoma (PSCC) are lacking. We aimed to analyze the benefit from perioperative radiotherapy (RT) according to HPV infection status.
Methods
Within an international, multicenter database of 1,254 patients (pts) with PSCC who received inguinal lymph node dissection (ILND) from Europe, United States, Brazil, United Kingdom and China, 507 had suitable clinical information. Kaplan-Meier and restricted mean survival time (RMST) examined the overall survival (OS) differences among HPV+ and HPV- patients according to the use of perioperative RT to involved regional lymph nodes. The analyses were also made after propensity score-matching (PSM; N=136). Multivariable Cox regression analyses for OS were also done. Finally, we looked at the genomic alterations landscape of PSCC from the Foundation Medicine database (N=199) to characterize HPV+ PSCC.
Results
Pts with HPV+ PSCC exhibited a lower clinical N-stage (p<0.001) and ILNM density (p<0.001). HPV+ patients had similar median OS (p=0.1) but longer RMST than HPV- patients at different time-points. Nevertheless, HPV+ patients treated with perioperative RT exhibited longer median OS (p=0.015) and longer RMST compared to HPV- pts. These findings were not confirmed with perioperative chemotherapy (p=0.19). In the PSM cohorts, HPV+ status remained significantly associated with longer OS after RT. In multivariable Cox regression analyses, pts with HPV+ PSCC exhibited a significantly improved OS compared with those with HPV- PSCC (HR: 0.12, 95%CI: 0.03-0.48; p=0.003). Among the several different genomic alterations frequencies, the top-altered genes (>20%) in HPV+ cases were PI3KCA (38.7%) and KMT2D(25.8%), whereas in HPV- cases these were TP53 (75.2%), CDKN2A (65%) and TERT (promoter region, 60.2%).
Conclusions
Perioperative RT was more effective in the subgroup of HPV+ PSCC. Reasons for enhanced RTsensitivity may also be related to the different landscape of genomic alterations. These results should be considered as hypothesis-generating and may inspire future prospective trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
LBA26 - Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease
Presenter: Ramaprasad Srinivasan
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
703MO - An integrated study of spatial dynamics and genomic alterations in renal cell carcinoma evolution
Presenter: Yue Zhao
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA27 - Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy
Presenter: Begona Perez Valderrama
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
704MO - Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100
Presenter: Petros Grivas
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
705MO - Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)
Presenter: Pavlos Msaouel
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
707MO - Longitudinal cohort analysis of patients with metastatic penile cancer treated in a large quaternary academic centre
Presenter: Wing Kin Liu
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
708MO - Metachronous contralateral testicular cancer in the cisplatin era: A population-based cohort study
Presenter: Ragnhild Hellesnes
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Giulia Baciarello
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Invited Discussant LBA26 and 703MO
Presenter: Cristina Suarez
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Invited Discussant LBA27, 704MO and 705MO
Presenter: Kilian Gust
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast